PMID- 36358776
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20221117
IS  - 2072-6694 (Print)
IS  - 2072-6694 (Electronic)
IS  - 2072-6694 (Linking)
VI  - 14
IP  - 21
DP  - 2022 Oct 30
TI  - Proton Pump Inhibitors Use and the Risk of Pancreatic Cancer: Evidence from 
      Eleven Epidemiological Studies, Comprising 1.5 Million Individuals.
LID - 10.3390/cancers14215357 [doi]
LID - 5357
AB  - Previous epidemiological studies have shown that proton pump inhibitor (PPI) may 
      modify the risk of pancreatic cancer. We conducted an updated systematic review 
      and meta-analysis of observational studies assessing the effect of PPI on 
      pancreatic cancer. PubMed, Embase, Scopus, and Web of Science were searched for 
      studies published between 1 January 2000, and 1 May 2022. We only included 
      studies that assessed exposure to PPI, reported pancreatic cancer outcomes, and 
      provided effect sizes (hazard ratio or odds ratio) with 95% confidence intervals 
      (CIs). We calculated an adjusted pooled risk ratio (RR) with 95%CIs using the 
      random-effects model. Eleven studies (eight case-control and three cohorts) that 
      reported 51,629 cases of pancreatic cancer were included. PPI was significantly 
      associated with a 63% increased risk of pancreatic cancer (RR(adj.) 1.63, 95%CI: 
      1.19-2.22, p = 0.002). Subgroup analysis showed that the pooled RR for 
      rabeprazole and lansoprazole was 4.08 (95%CI: 0.61-26.92) and 2.25 (95%CI: 
      0.83-6.07), respectively. Moreover, the risk of pancreatic cancer was established 
      for both the Asian (RR(adj.) 1.37, 95%CI: 0.98-1.81) and Western populations 
      (RR(adj).2.76, 95%CI: 0.79-9.56). The findings of this updated meta-analysis 
      demonstrate that the use of PPI was associated with an increased risk of 
      pancreatic cancer. Future studies are needed to improve the quality of evidence 
      through better verification of PPI status (e.g., patient selection, duration, and 
      dosages), adjusting for possible confounders, and ensuring long-term follow-up.
FAU - Poly, Tahmina Nasrin
AU  - Poly TN
AD  - Graduate Institute of Biomedical Informatics, College of Medical Science and 
      Technology, Taipei Medical University, Taipei 110301, Taiwan.
AD  - International Center for Health Information Technology (ICHIT), Taipei Medical 
      University, Taipei 110301, Taiwan.
AD  - Research Center of Big Data and Meta-Analysis, Wan Fang Hospital, Taipei Medical 
      University, Taipei 110301, Taiwan.
FAU - Islam, Md Mohaimenul
AU  - Islam MM
AUID- ORCID: 0000-0001-6026-2748
AD  - Graduate Institute of Biomedical Informatics, College of Medical Science and 
      Technology, Taipei Medical University, Taipei 110301, Taiwan.
AD  - Research Center of Big Data and Meta-Analysis, Wan Fang Hospital, Taipei Medical 
      University, Taipei 110301, Taiwan.
FAU - Walther, Bruno Andreas
AU  - Walther BA
AUID- ORCID: 0000-0002-0425-1443
AD  - Alfred-Wegener-Institut Helmholtz-Zentrum fur Polar-und Meeresforschung, Am 
      Handelshafen 12, D-27570 Bremerhaven, Germany.
FAU - Lin, Ming-Chin
AU  - Lin MC
AUID- ORCID: 0000-0001-9624-9705
AD  - Graduate Institute of Biomedical Informatics, College of Medical Science and 
      Technology, Taipei Medical University, Taipei 110301, Taiwan.
AD  - Department of Neurosurgery, Shuang Ho Hospital, Taipei Medical University, New 
      Taipei City 235041, Taiwan.
FAU - Li, Yu-Chuan Jack
AU  - Li YJ
AD  - Graduate Institute of Biomedical Informatics, College of Medical Science and 
      Technology, Taipei Medical University, Taipei 110301, Taiwan.
AD  - International Center for Health Information Technology (ICHIT), Taipei Medical 
      University, Taipei 110301, Taiwan.
AD  - Research Center of Big Data and Meta-Analysis, Wan Fang Hospital, Taipei Medical 
      University, Taipei 110301, Taiwan.
AD  - Department of Dermatology, Wan Fang Hospital, Taipei 116, Taiwan.
LA  - eng
PT  - Journal Article
DEP - 20221030
PL  - Switzerland
TA  - Cancers (Basel)
JT  - Cancers
JID - 101526829
PMC - PMC9658965
OTO - NOTNLM
OT  - meta-analysis
OT  - omeprazole
OT  - pancreatic cancer
OT  - proton pump inhibitor
COIS- The authors declare no conflict of interest.
EDAT- 2022/11/12 06:00
MHDA- 2022/11/12 06:01
PMCR- 2022/10/30
CRDT- 2022/11/11 01:07
PHST- 2022/08/15 00:00 [received]
PHST- 2022/10/16 00:00 [revised]
PHST- 2022/10/27 00:00 [accepted]
PHST- 2022/11/11 01:07 [entrez]
PHST- 2022/11/12 06:00 [pubmed]
PHST- 2022/11/12 06:01 [medline]
PHST- 2022/10/30 00:00 [pmc-release]
AID - cancers14215357 [pii]
AID - cancers-14-05357 [pii]
AID - 10.3390/cancers14215357 [doi]
PST - epublish
SO  - Cancers (Basel). 2022 Oct 30;14(21):5357. doi: 10.3390/cancers14215357.